| Budget Amount *help |
¥45,760,000 (Direct Cost: ¥35,200,000、Indirect Cost: ¥10,560,000)
Fiscal Year 2018: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
Fiscal Year 2017: ¥11,570,000 (Direct Cost: ¥8,900,000、Indirect Cost: ¥2,670,000)
Fiscal Year 2016: ¥11,570,000 (Direct Cost: ¥8,900,000、Indirect Cost: ¥2,670,000)
Fiscal Year 2015: ¥12,740,000 (Direct Cost: ¥9,800,000、Indirect Cost: ¥2,940,000)
|
|---|
| Outline of Final Research Achievements |
To establish the personalized preemptive medicine against Alzheimer disease (AD), we have to understand the effect of each risk factor on the pathological process of AD. In this research, we investigated the pathological effects of known genetic risk factors in vitro and in vivo. We revealed that, among the risk factors, PICALM and BIN1 affect the Aβ production pathway. In contrast, INPP5D and DAP12 modulates the response of microglia against Aβ deposition. In addition, we found that BIN1 is involved in the propagation of tau pathology. Moreover, we identified several genes that affect the aggregation of tau. Also, we found KLK7, an Aβ degrading enzyme, as a novel risk factor expressed in the astrocytes.
|
